The company's proprietary AOC platform combines the tissue selectivity of monoclonal antibodies with the precision of oligonucleotide therapies to access previously undruggable tissue and cell types and more effectively target underlying genetic drivers of diseases. Avidity's lead product candidate, AOC 1001, is designed to treat myotonic dystrophy type 1, and its other muscle programs focus on the treatment of muscle atrophy, Duchenne muscular dystrophy, facioscapulohumeral muscular dystrophy, and Pompe disease. The company also has development efforts focused on immune and other cell types. Avidity is committed to revolutionizing the delivery of RNA therapeutics and delivering breakthrough therapies to patients.